About Motilent
We don’t know enough about how the digestive system really works.
The gastrointestinal tract spans around 9 meters and is responsible for absorbing nutrients from our food. Beyond this it is home to trillions of microbes and thousands of strains of bacteria all contributing to our metabolic and immune health. Coordinating the gastrointestinal tract is the enteric nervous system and brain-gut axis that gives rise to our visceral sensations and allow us to feel our emotions. With all this complexity, it comes as little surprise that things can often go wrong.
With around 20% of the population currently suffering from some form of gastrointestinal disorder, the management of digestive diseases presents an ever-growing burden for health care services.
Motilent’s mission is to change the way we see the gut. We have spent the last 5 years developing new imaging technology that is helping researchers and clinicians understand how the digestive tract works. Our key clinical focus area is Crohn’s Disease, a debilitating inflammatory condition affecting people of all ages and our first product GIQuant aims to help clinicians to identify earlier when patients stop responding to immunotherapy.
Innovation at Motilent however never stops. Get in touch with us today to find out how we will help you see the future of gastrointestinal physiology with medical imaging.
Our management team
-
Dr Alex Menys
Founder and Chief Executive Officer
-
Alex founded Motilent in 2013 to expedite collaborative research in his field of medical image analysis for gastrointestinal (GI) disorders. Since then, Motilent has grown to working across a range of GI specialties in research and has produced it's first clinically available product for Crohn's disease monitoring - GIQuant. Alex holds master degrees in Biochemistry and Medical Physics, a PhD in MRI imaging and spent 2 years on the board of an AIM listed UK medical device company.
-
Laurence Bourn
Chief Technical Officer
-
Laurence brings a wealth of experience to Motilent working for the past 15 years in medical imaging at some of the most important companies in the space. As CTO, Laurence will help Motilent develop its portfolio of technologies for use in digestive disease and oversee its transition into an 'at market' Medical Device company.
Stuart A Taylor, Consultant Radiologist and Professor of Medical Imaging, UCLDynamic ‘cine’ MRI offers a new and potentially powerful perspective on gastrointestinal function, especially in conditions like Crohn’s where hypo-motility is related to disease activity. Objective assessment of this data with GIQuant could represent an important advance in how we quantify this in the clinic
